Covid-19 vaccine maker Oxford Biomedica enjoys boost in revenue
Oxford Biomedica, which helped manufacture the AstraZeneca Covid-19 vaccine, enjoyed a revenue increase of more than 60%, thanks to its frontline position in the fight against the pandemic.
The London-listed cell and gene therapy group raked in £142.8m as of December 31, up from £87.7m in 2020.
CEO and interim chairman Dr Roch Doliveux hailed the “outstanding” financial performance, which also saw the company produce more than 100 million doses of vaccine during the partnership with AstraZeneca.
The biotech company has since signed two new partnerships with fellow biotechs Immatics and Arcellx, after its commercial and bioprocessing revenues jumped nearly 90% in the 12-month period.
“2022 will be another important year as we execute our strategy to become a global leader in viral vectors, delivering life-changing therapies and vaccines to patients,” the interim CEO said in a statement.
“With the rapidly growing market for outsourced vector manufacturing supply, we see significant potential to build on our success with lentiviral vectors and extend the reach of our innovative process development and manufacturing to all classes. of viral vectors.”